Skip to search formSkip to main contentSkip to account menu

incobotulinumtoxinA

Known as: BoNT-A 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Botulinum Toxin Type ANeuromuscular AgentsNeurotoxins
INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT

Narrower (3)

NT 201Xeominbocouture

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
Objective This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of… 
Highly Cited
2017
Highly Cited
2017
Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity
Objective: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA… 
2017
2017
Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.
Highly Cited
2016
Highly Cited
2016
Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity
Introduction: Efficacy and safety of incobotulinumtoxinA in post‐stroke upper‐limb spasticity were studied. Methods: Subjects… 
2013
2013
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous… 
2013
2013
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia
IncobotulinumtoxinA (Xeomin®, NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and… 
Highly Cited
2011
Highly Cited
2011
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling… 
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia
2011
2011
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
  • M. Imhof, U. Kühne
  • The Journal of clinical and aesthetic dermatology
  • 2011
  • Corpus ID: 43319090
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free… 
Highly Cited
2010
Highly Cited
2010
Noninferiority of IncobotulinumtoxinA, Free from Complexing Proteins, Compared with Another Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License